Skip to content

CTI BIOPHARMA CORP

Delisted

CIK 891293fmd_1B60HC0BNDXKDP7YA8MVS997V1Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2009 to Mar 31, 2023, 55 periods

Latest annual · FY2022

Millions
Total revenues
54
Gross profit
50
Operating income
(80)
Net income
(93)
Free cash flow
(85)

Latest quarter · Q1 FY2023

Millions
Total revenues
24
Gross profit
23
Operating income
(9)
Net income
(13)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2019 to FY2022
+152.7%
Revenue, 5 yearsFY2017 to FY2022
+16.5%
Net income, 5 yearsFY2017 to FY2022
n/m

CTI BIOPHARMA CORP financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2022FY2021ChangeSource
Revenue$53.9 million$010-K 2023-03-06 · proof
Gross profit$50.4 million$010-K 2023-03-06 · proof
Operating income-$79.8 million-$95.3 million10-K 2023-03-06 · proof
Net income-$93 million-$97.9 million10-K 2023-03-06 · proof
Cash from operating activities-$81.2 million-$84.9 million10-K 2023-03-06 · proof
Total assets$125.9 million$72.4 million+73.8%10-K 2023-03-06 · proof
Total liabilities$143.5 million$68.7 million+109%10-K 2023-03-06 · proof
Cash and cash equivalents$30.4 million$65.4 million-53.5%10-K 2023-03-06 · proof
Total debt$95.9 million$47.4 million+102.4%10-K 2023-03-06 · proof
What was CTI BIOPHARMA CORP's revenue in fiscal 2022?
CTI BIOPHARMA CORP reported revenue of $53.9 million for fiscal 2022 (the year ended Dec 31, 2022), against $0 the year before. Source: the 10-K filed with the SEC on Mar 6, 2023. SEC
What was CTI BIOPHARMA CORP's gross profit in fiscal 2022?
CTI BIOPHARMA CORP reported gross profit of $50.4 million for fiscal 2022 (the year ended Dec 31, 2022), against $0 the year before. Source: the 10-K filed with the SEC on Mar 6, 2023. SEC
What was CTI BIOPHARMA CORP's operating income in fiscal 2022?
CTI BIOPHARMA CORP reported operating income of -$79.8 million for fiscal 2022 (the year ended Dec 31, 2022), against -$95.3 million the year before. Source: the 10-K filed with the SEC on Mar 6, 2023. SEC
What was CTI BIOPHARMA CORP's net income in fiscal 2022?
CTI BIOPHARMA CORP reported net income of -$93 million for fiscal 2022 (the year ended Dec 31, 2022), against -$97.9 million the year before. Source: the 10-K filed with the SEC on Mar 6, 2023. SEC
What was CTI BIOPHARMA CORP's cash from operating activities in fiscal 2022?
CTI BIOPHARMA CORP reported cash from operating activities of -$81.2 million for fiscal 2022 (the year ended Dec 31, 2022), against -$84.9 million the year before. Source: the 10-K filed with the SEC on Mar 6, 2023. SEC
What are CTI BIOPHARMA CORP's total assets?
As of Dec 31, 2022, CTI BIOPHARMA CORP reported total assets of $125.9 million, against $72.4 million a year earlier (+73.8%). Source: the 10-K filed with the SEC on Mar 6, 2023. SEC
What are CTI BIOPHARMA CORP's total liabilities?
As of Dec 31, 2022, CTI BIOPHARMA CORP reported total liabilities of $143.5 million, against $68.7 million a year earlier (+109%). Source: the 10-K filed with the SEC on Mar 6, 2023. SEC
What are CTI BIOPHARMA CORP's cash and cash equivalents?
As of Dec 31, 2022, CTI BIOPHARMA CORP reported cash and cash equivalents of $30.4 million, against $65.4 million a year earlier (-53.5%). Source: the 10-K filed with the SEC on Mar 6, 2023. SEC
What is CTI BIOPHARMA CORP's total debt?
As of Dec 31, 2022, CTI BIOPHARMA CORP reported total debt of $95.9 million, against $47.4 million a year earlier (+102.4%). Source: the 10-K filed with the SEC on Mar 6, 2023. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:891293&period_type=annual&limit=5"

Information only, not investment advice.